Micafungin Inresa

Micafungin, the active ingredient in Micafungin Inresa, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive fungal infections such as candidemia, invasive candidiasis, esophageal candidiasis, and serves as prophylaxis in neutropenic patients. It is indicated for patients with compromised immune systems who are at high risk of systemic fungal disease.

GNH USA supplies Micafungin Inresa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics for injectable products.

Micafungin is an echinocandin antifungal that targets invasive Candida infections and related conditions. - Invasive candidiasis: provides rapid eradication of deep‑tissue Candida infections, improving survival. - Candidemia: clears Candida organisms from the bloodstream, reducing systemic spread. - Esophageal candidiasis: resolves mucosal lesions and alleviates dysphagia and pain. - Prophylaxis in neutropenic patients: prevents occurrence of invasive fungal infections during periods of severe neutropenia.

Micafungin may be associated with a range of adverse reactions, most of which are related to its intravenous administration and antifungal activity. Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate feeling of sickness. - Elevated liver enzymes: reversible increase in ALT/AST. Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Hypersensitivity reactions: including anaphylaxis. - Severe infusion-related reactions: hypotension or bronchospasm.

When using Micafungin, clinicians should consider several safety measures to minimise risk. - Renal function: assess baseline and monitor during therapy. - Liver function: evaluate hepatic enzymes before and during treatment. - Drug interactions: review concomitant medications for potential CYP interactions. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Infusion: administer under medical supervision; monitor for reactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; awareness of the interaction level helps guide clinical decisions. Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise toxicity risk. - Rifampin: strong enzyme inducer may reduce micafungin levels. Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may affect hepatic metabolism. - Warfarin: potential alteration of anticoagulant effect. - Statins (e.g., simvastatin): possible increased risk of myopathy.